Disease-modifying therapies can reduce multiple sclerosis relapse rates. Jonathan E. Howard, MD, a neurologist and associate professor of neurology and psychiatry at
NYU Grossman School of Medicine provides insight on factors that contribute to switching disease modifying therapies in MS due to breakthrough disease activity or inadequate response to therapy.
Christoph U. Correll, MD, professor of psychiatry and molecular medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital, discusses how 2 new VMAT2 agents are changing the management of tardive dyskinesia.
Amos Katz, MD, a board-certified neurologist, discusses the role and benefit of initiating appropriate early disease-modifying therapy to delay disability progression in patients with multiple sclerosis.
Jonathan L. Carter, MD, neuromuscular disease specialist and associate professor of neurology at the Mayo Clinic Alix School of Medicine, Phoenix/Scottsdale, Arizona, discusses the clinical utility of CD20-targeted B-cell therapy for relapsing forms of multiple sclerosis.
The transition from relapsing-remitting multiple sclerosis to secondary progressive disease can be easily missed. Neurologist and clinical researcher Mark S. Freedman, MD, CSPQ, FANA, FAAN, FRCPC, discusses the assessment and management of disease progression in relapsing forms of multiple sclerosis.
Fatigue is one of the most frequently reported symptoms in people with MS; however, its etiology and presentation can vary from patient to patient. In this interview, approaches to identifying fatigue and a team-based strategy for minimizing its impact on patients’ lives are discussed.
